YahooSeptember 15, 2026 at 5:08 AM NYLast Month
ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio
By John Vandermosten, CFA NYSE: ATNM READ THE FULL ATNM RESEARCH REPORT We are initiating coverage of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) and assign a valuation of $4.00 per share. This valuation is based on our estimates for successful development, approval, and commercialization of ATNM-400 in solid tumors, Actimab-A, Iomab-ACT, and Iomab-B in acute myeloid leukemia (AML), solid tumors,
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
